1/8
08:00 am
huma
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
Medium
Report
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
1/7
11:58 am
huma
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
1/5
08:42 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
1/5
08:06 am
huma
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel [Yahoo! Finance]
Medium
Report
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel [Yahoo! Finance]
1/5
08:00 am
huma
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
Medium
Report
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
12/22
10:25 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
12/22
08:10 am
huma
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair [Yahoo! Finance]
Medium
Report
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair [Yahoo! Finance]
12/22
08:00 am
huma
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
Medium
Report
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
12/21
01:08 am
huma
Medium
Report
12/16
04:37 pm
huma
Humacyte (NASDAQ:HUMA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
08:00 am
huma
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
Medium
Report
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
12/13
01:10 am
huma
Medium
Report
12/10
02:22 pm
huma
Humacyte (HUMA): Benchmark Remains Bullish on Stock [Yahoo! Finance]
Low
Report
Humacyte (HUMA): Benchmark Remains Bullish on Stock [Yahoo! Finance]
12/1
07:20 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/1
07:20 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/27
06:40 pm
huma
Humacyte (HUMA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Humacyte (HUMA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/21
08:05 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $6.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $6.00 price target on the stock.
11/20
09:46 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
11/20
08:00 am
huma
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
Medium
Report
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
11/13
01:39 pm
huma
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at Benchmark Co. from $14.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at Benchmark Co. from $14.00 to $11.00. They now have a "buy" rating on the stock.
11/13
08:38 am
huma
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) [Yahoo! Finance]
Medium
Report
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) [Yahoo! Finance]
11/13
08:00 am
huma
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
Medium
Report
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
11/12
03:02 pm
huma
Humacyte Inc (HUMA) Q3 2025 Earnings Call Highlights: Strong Symvess Sales Growth Amidst ... [Yahoo! Finance]
Low
Report
Humacyte Inc (HUMA) Q3 2025 Earnings Call Highlights: Strong Symvess Sales Growth Amidst ... [Yahoo! Finance]
11/12
12:27 pm
huma
Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
12:23 pm
huma
Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise [Seeking Alpha]
Low
Report
Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise [Seeking Alpha]